

Nurtec™ ODT (rimegepant) Prior and Reauthorization Worksheet

Your patient's health plan may require an authorization for initial approval (prior authorization, or PA) of Nurtec ODT, as well as for use after a specified amount of time (reauthorization, or RA). Depending on the plan, an RA may be required for your patient to continue treatment with Nurtec ODT after 3, 6, or 12 months of use.

This tool can help you prepare your PA and RA requests for appropriate patients. **Please note that PA and RA criteria may vary by plan, so be sure to confirm the required information and documentation before beginning your request.**

Possible PA/RA criteria for Nurtec ODT coverage

The information below represents potential criteria that your patient may need to meet for the health plan to approve initial or continued use of Nurtec ODT. It is not intended to be a conclusive or exhaustive list.

PA CRITERIA ASSESSMENT		
Is your patient 18 years of age or older? ¹⁻⁴	Yes	No
Is Nurtec ODT being prescribed for acute treatment of migraine with or without aura? ¹⁻⁶	Yes	No
Does your patient suffer from moderate or severe migraine? ^{1,3,5}	Yes	No
		ICD-10-CM Codes (See page 2 for possible ICD-10-CM codes to include)
Has your patient tried one or more triptans? ²⁻⁶	Yes	No
		List the names of previous triptan therapies, including dates of use, dosage, and frequency
Did your patient discontinue triptan therapy due to therapeutic failure, contraindication, or intolerance/adverse events? ²⁻⁶	Yes	No
		Describe reasons for discontinuation
Was Nurtec ODT prescribed in consultation with a specialist? ^{3,5}	Yes	No
		List the specialty (eg, neurologist, pain specialist) and name of specialist
RA CRITERIA ASSESSMENT		
When did your patient start treatment with Nurtec ODT?	Date	
Per month, how often does your patient use Nurtec ODT?	Approximate use per month	
Did your patient experience any adverse events while taking Nurtec ODT? ⁴	Yes	No
		List any side effects
Did your patient have a positive clinical response to Nurtec ODT? ^{4,5}	Yes	No
		Describe the positive clinical response
Is your patient currently taking other migraine therapies in addition to Nurtec ODT?	Yes	No
		List other migraine therapies

Be sure to have the RA information ready before the end of the specified time period to prevent any delays in therapy.

INDICATION

Nurtec ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Nurtec ODT is not indicated for the preventive treatment of migraine.

Please see next page for Important Safety Information and click here for full Prescribing Information.

Documentation to consider including with your request (if required by the health plan)

- Any health plan-specific PA forms
- Letter of Medical Necessity (important for patients who may not meet all PA criteria)
- Your patient's medical records (eg, previous/current therapies, existing comorbidities, allergies)
- Additional documentation to support treatment with Nurtec ODT, such as
 - Nurtec ODT Prescribing Information
 - Nurtec ODT FDA approval letter (this can be found on the FDA website)
 - Peer-reviewed literature, including published clinical trial data for Nurtec ODT

Examples of ICD-10-CM codes for migraine

The codes listed below may be appropriate to include with your request for your patients with migraine. Please refer to an ICD-10-CM resource for additional codes that may be applicable to your patient.

ICD-10-CM CODE ⁷	DESCRIPTION ⁷
G43	Migraine
G43.0	Migraine without aura
G43.1	Migraine with aura
G43.9	Migraine, unspecified

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding:* It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment.

Renal impairment: Avoid use in patients with end-stage renal disease.

Please click here for full [Prescribing Information](#).

References: **1.** Nurtec ODT [package insert]. New Haven, CT: Biohaven Pharmaceuticals, Inc. **2.** ConnectiCare. Commercial/healthcare exchange PA criteria. [https://www.connecticare.com/content/dam/connecticare/pdfs/providers/pharmacy/commercial/Nurtec ODT PA CCI.pdf](https://www.connecticare.com/content/dam/connecticare/pdfs/providers/pharmacy/commercial/Nurtec%20ODT%20PA%20CCI.pdf). Updated August 3, 2020. Accessed September 23, 2020. **3.** Medical Mutual. Drug policy. <https://www.medmutual.com/-/media/MedMutual/Files/Providers/Prior-Auth-Rx/Acute-Oral-CGRP-Antagonists.ashx>. Updated March 19, 2020. Accessed September 23, 2020. **4.** BlueShield of Northeastern New York. Drug therapy guidelines. [https://www.bsny.com/content/dam/COMMON/nonsecure/provider/drug-therapy-guidelines/B-C-D/calcitonin-gene-related-peptide-\(cgrp\)-antagonists-acute-treatment.pdf](https://www.bsny.com/content/dam/COMMON/nonsecure/provider/drug-therapy-guidelines/B-C-D/calcitonin-gene-related-peptide-(cgrp)-antagonists-acute-treatment.pdf). Updated April 23, 2020. Accessed September 23, 2020. **5.** UnitedHealthcare. Nurtec ODT (rimegepant)-Prior authorization/medical necessity. <https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/h-p/COMM-PA-Med-Nec-Nurtec.pdf>. Published September 1, 2020. Accessed September 23, 2020. **6.** Amerigroup. Nurtec ODT (rimegepant). https://providers.amerigroup.com/AGP%20Documents/PHARM_ALL_Nurtec.pdf. Updated August 7, 2020. Accessed September 23, 2020. **7.** Center for Diseases Control and Prevention. ICD-10-CM tabular list of diseases and injuries. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2020. Updated June 19, 2019. Accessed September 23, 2020